COMMUNIQUÉS West-GlobeNewswire

BioSyent to Acquire Oral Science Inc.
09/02/2026
Accretive Transaction with Combined Companies’ Pro-Forma Revenue in Excess of $70.00 Million and EBITDA (1) in Excess of $15.75 Million (TTM Sept 30, 2025) MISSISSAUGA, Ontario, Feb. 09, 2026 (GLOBE NEWSWIRE) -- [...]
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
09/02/2026
TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team led by Dr. Justin Chun at the University of Calgary [...]
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
09/02/2026
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita [...]
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
09/02/2026
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week data support the [...]
Kraig Biocraft Laboratories Poised for Explosive Spider Silk Production Growth
09/02/2026
2026 Production Plan Set for a Record 10 Metric Tons of Recombinant Spider Silk Cocoon Per Month ANN ARBOR, Mich., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig [...]
Oruka Therapeutics to Participate in Multiple Upcoming Conferences
09/02/2026
MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update
09/02/2026
– First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million – First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million – Conference [...]
Avis aux médias : La journée Tout le monde en rouge attire l’attention sur la crise des maladies cardiaques chez les femmes au Canada
09/02/2026
OTTAWA, Ontario, 09 févr. 2026 (GLOBE NEWSWIRE) -- Le 13 février, la population canadienne célébrera la Journée Tout le monde en rouge , une campagne nationale de sensibilisation à la santé cardiaque des femmes. [...]
Aerska Raises $39M Series A Financing led by EQT Dementia Fund and age1 to Systemically Deliver RNA Medicines to the Brain
09/02/2026
Brings total funds raised to $60 million since launch, months after its seed funding announcement in October 2025 Appoints Arno de Wilde, Philip Scheltens and Alex Colville to its Board of Directors DUBLIN and LONDON, [...]
SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy
09/02/2026
All patients dosed with SPVN06 in Phase I/II trial continue to demonstrate a favorable safety profile Initial data readout for this novel gene-agnostic therapy expected in 2027 Paris, February 9, 2026 – SparingVision (“ [...]
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
09/02/2026
FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the [...]
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
09/02/2026
Study to assess safety, efficacy and treatment experience of starting inhaled insulin in youth aged 10 to <18 years recently diagnosed with T1D DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 09, 2026 (GLOBE [...]
BioPorto A/S Appoints Chief Financial Officer
09/02/2026
February 9, 2026 Announcement no. 2 BioPorto A/S Appoints Chief Financial Officer BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced the appointment of Klaus Juhl Wulff as its new Executive Vice President (EVP) and [...]
Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium
09/02/2026
Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPDR) with associated [...]
Notification of managers’ transactions
09/02/2026
ANNOUNCEMENT NO. 301 9 February 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology
09/02/2026
PRESS RELEASE Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option by [...]
Bavarian Nordic – Completion of Share Buy-Back Program
09/02/2026
COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reaching an aggregate [...]
Avacta appoints Francis Wilson as Chief Scientific Officer
09/02/2026
LONDON and PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology [...]
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
09/02/2026
Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia Rilzabrutinib is the first and only investigational BTKi for warm [...]

Pages